Patents by Inventor John Lawson Stanford
John Lawson Stanford has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8512694Abstract: The present invention relates to a method of producing rough strains of a bacterium, such as Mycobacterium obuense, said method comprising exposing said bacterium to a sulfone and/or sulfonamide (such as 4,4?-Diaminodiphenyl sulfone or an analogue thereof). A rough strain of Mycobacterium obuense producible by said method and uses thereof. In particular, uses of a rough strain of Mycobacterium obuense deposited under the Budapest Treaty at the NCTC with the accession number NCTC 13365.Type: GrantFiled: December 5, 2011Date of Patent: August 20, 2013Assignee: Bioeos LimitedInventors: John Lawson Stanford, Cynthia Ann Stanford, Graham McIntyre, Oscar Adelmo Bottasso
-
Patent number: 8349314Abstract: Use of whole cells of bacteria from the genera of aerobic organisms in the order of Actinomycetales in the manufacture of a medicament for the treatment or prevention of Type II diabetes and/or obesity and methods of treating or preventing Type II diabetes and/or obesity in a subject by administering an effective amount of a composition comprising a whole cell of a bacterium from a genera of aerobic organisms in the order of Actinomycetales to said subject. Preferably the bacteria is from one or more of the following genera for example: Gordonia, Rhodococcus, Tsukamurella, Nocardia, Dietzia and Mycobacterium.Type: GrantFiled: August 26, 2008Date of Patent: January 8, 2013Assignee: BIOEOS LimitedInventors: John Lawson Stanford, Cynthia Ann Stanford, Graham McIntyre, Oscar Adelmo Bottasso
-
Publication number: 20120082699Abstract: The present invention relates to a method of producing rough strains of a bacterium, such as Mycobacterium obuense, said method comprising exposing said bacterium to a sulfone and/or sulfonamide (such as 4,4?-Diaminodiphenyl sulfone or an analogue thereof). A rough strain of Mycobacterium obuense producible by said method and uses thereof. In particular, uses of a rough strain of Mycobacterium obuense deposited under the Budapest Treaty at the NCTC with the accession number NCTC 13365.Type: ApplicationFiled: December 5, 2011Publication date: April 5, 2012Applicant: BIOEOS LIMITEDInventors: John Lawson Stanford, Cynthia Ann Stanford, Graham McIntyre, Oscar Adelmo Bottasso
-
Patent number: 8071354Abstract: The present invention relates to a method of producing rough strains of a bacterium, such as Mycobacterium obuense, said method comprising exposing said bacterium to a sulfone and/or sulfonamide (such as 4,4?-Diaminodiphenyl sulfone or an analogue thereof). A rough strain of Mycobacterium obuense producible by said method and uses thereof. In particular, uses of a rough strain of Mycobacterium obuense deposited under the Budapest Treaty at the NCTC with the accession number NCTC 13365.Type: GrantFiled: December 19, 2006Date of Patent: December 6, 2011Assignee: Bioeos LimitedInventors: John Lawson Stanford, Cynthia Ann Stanford, Graham McIntyre, Oscar Adelmo Bottasso
-
Publication number: 20090304749Abstract: The present invention relates to a method of producing rough strains of a bacterium, such as Mycobacterium obuense, said method comprising exposing said bacterium to a sulfone and/or sulfonamide (such as 4,4?-Diaminodiphenyl sulfone or an analogue thereof). A rough strain of Mycobacterium obuense producible by said method and uses thereof. In particular, uses of a rough strain of Mycobacterium obuense deposited under the Budapest Treaty of NCTC with the accession number NCTC 13365.Type: ApplicationFiled: December 19, 2006Publication date: December 10, 2009Applicant: BIOEOS LIMITEDInventors: John Lawson Stanford, Cynthia Ann Stanford, Graham McIntyre, Oscar Adelmo Bottasso
-
Publication number: 20090226490Abstract: Use of a composition comprising a whole cell of a bacterium from a genus of aerobic organisms in the order of Actinomycetales in the manufacture of a medicament for modulating the immune response of a recipient wherein said composition is administered to a subject and said recipient is exposed to a bodily of said subject whilst said recipient is an infant. Preferably the medicament is used for the prevention and/or treatment of one or more of: an infection, an allergy, an autoimmune-based disease and a neoplasm in said recipient.Type: ApplicationFiled: December 19, 2006Publication date: September 10, 2009Inventors: John Lawson Stanford, Cynthia Ann Stanford, Graham McIntyre, Oscar Adelmo Bottasso
-
Patent number: 7579009Abstract: An immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, wherein said immune modulator composition in use modifies a cellular immune response.Type: GrantFiled: September 5, 2003Date of Patent: August 25, 2009Assignee: University College LondonInventors: Graham McIntyre, John Lawson Stanford, Cynthia Ann Stanford, Oscar Adelmo Bottasso
-
Publication number: 20090162324Abstract: Use of whole cells of bacteria from the genera of aerobic organisms in the order of Actinomycetales in the manufacture of a medicament for the treatment or prevention of stress-induced pulmonary haemorrhage (SIPH), preferably exercise induced pulmonary haemorrhage (EIPH), and methods of treating or preventing SIPH, preferably EIPH, in a subject by administering an effective amount of a composition comprising a whole cell of a bacterium from a genera of aerobic organisms in the order of Actinomycetales to said subject. Preferably the aerobic organism is from one or more of the following genera for example: Tsukamurella, Rhodococcus, Gordonia, Nocardia, Dietzia and Mycobacterium.Type: ApplicationFiled: December 19, 2006Publication date: June 25, 2009Applicant: BIOEOS LIMITEDInventors: John Lawson Stanford, Cynthia Ann Stanford, Graham McIntyre, Oscar Adelmo Bottasso
-
Publication number: 20090060877Abstract: Use of whole cells of bacteria from the genera of aerobic organisms in the order of Actinomycetales in the manufacture of a medicament for the treatment or prevention of Type II diabetes and/or obesity and methods of treating or preventing Type II diabetes and/or obesity in a subject by administering an effective amount of a composition comprising a whole cell of a bacterium from a genera of aerobic organisms in the order of Actinomycetales to said subject. Preferably the bacteria is from one or more of the following genera for example: Gordonia, Rhodococcus, Tsukamurella, Nocardia, Dietzia and Mycobacterium.Type: ApplicationFiled: August 26, 2008Publication date: March 5, 2009Applicant: BIOEOS LIMITEDInventors: John Lawson Stanford, Cynthia Ann Stanford, Graham Mclntyre, Oscar Adelmo Bottasso
-
Patent number: 7442374Abstract: This invention relates to a method for treating or preventing (including immunising against) post-wearing multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS) in a subject comprising administering an effective amount of a pharmaceutical composition or immune modulator composition comprising a whole cell of a bacterium from one or more of the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, to said subject. In addition the method relates to the use of an immune modulator composition or a pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, in the manufacture of a medicament for the treatment or prevention of post-wearing multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS).Type: GrantFiled: July 19, 2004Date of Patent: October 28, 2008Assignee: UCL BioMedica PlcInventors: Oscar Adelmo Bottasso, Graham McIntyre, Cynthia Ann Stanford, John Lawson Stanford
-
Patent number: 7413728Abstract: Use of an immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, for use in the manufacture of a medicament for the treatment of an autoimmune disease or autoimmune disorder, including certain vascular disorders.Type: GrantFiled: November 12, 2004Date of Patent: August 19, 2008Assignee: UCL Biomedica PLCInventors: Graham McIntyre, John Lawson Stanford, Cynthia Ann Stanford, Oscar Adelmo Bottasso
-
Patent number: 6432714Abstract: Antigenic and/or immunoregulatory material derived from Mycobacterium vaccae is useful in the prophylaxis or therapy of AIDS with or without associated tuberculosis.Type: GrantFiled: February 27, 2001Date of Patent: August 13, 2002Assignee: Stanford Rook LimitedInventors: John Lawson Stanford, Graham A. W. Rook
-
Publication number: 20020001596Abstract: Antigenic and/or immunoregulatory material derived from Mycobacterium vaccae is useful in the prophylaxis or therapy of AIDS with or without associated tuberculosis.Type: ApplicationFiled: February 27, 2001Publication date: January 3, 2002Inventors: John Lawson Stanford, Graham A.W. Rook
-
Patent number: 6210684Abstract: Antigenic and/or immunoregulatory material derived from Mycobacterium vaccae is useful for delaying the onset of AIDS with or without associated tuberculosis.Type: GrantFiled: May 16, 1995Date of Patent: April 3, 2001Assignee: Stranford Rock LimitedInventors: John Lawson Stanford, Graham Arthur William Rook
-
Patent number: 6056964Abstract: A method for delaying or preventing the growth or spread of a malignant neoplasm by administering to a subject in need material which comprises killed cells of Mycobacterium vaccae in an amount sufficient at least to delay or prevent the growth or spread of the neoplasm.Type: GrantFiled: October 25, 1996Date of Patent: May 2, 2000Assignee: Stanford Rook LimitedInventors: Graham Arthur William Rook, John Lawson Stanford
-
Patent number: 5885588Abstract: Antigenic and/or immunoregulatry material derived from Mycobacterium vaccae is useful in the treatment of mental diseases associated with an autoimmune reaction initiated by an infection and/or the auto immunologically mediated consequences (other than uveitis) of chronic infection.Type: GrantFiled: February 14, 1995Date of Patent: March 23, 1999Assignee: University College LondonInventors: John Lawson Stanford, Graham Arthur William Rook
-
Patent number: 5833996Abstract: Immunoregulatory material derived from Mycobacterium vaccae, especially dead cells of M. vaccae, are useful for the treatment of pathological conditions (other than mycobacterial disease and arthritic disease) in a patient in which the patient's IgG shows an abnormally high proportion of agalactosyl IgG and for the treatment of chronic inflammatory disorders (other than an arthritic disease) caused or accompanied by an abnormally high release from macrophages of interleukin-6 and/or tumor necrosis factor.Type: GrantFiled: May 16, 1995Date of Patent: November 10, 1998Assignee: University College LondonInventors: John Lawson Stanford, Graham Arthur William Rook